secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-08-11T11:20:34+00:00
Accession:  0001193125-26-343434
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Q2 net loss $55.3M; vopimetostat combo 92% ORR, cash $1B
--------------------------------------------------------------

- Q2 net loss $55.3M ($0.37/share) vs $38.9M ($0.35/share) YoY; cash $1.0B as of June 30, 2026.
- Vopimetostat + daraxonrasib showed 92% ORR and 90% 6-month PFS in MTAP-deleted, RAS-mutant pancreatic cancer; advancing to Phase 3.
- Data to be presented at ESMO 2026 (Oct 23-27, Madrid); plans to finalize Phase 3 design in 2H 2026.
- Fatma Ocak appointed Chief Commercialization Officer effective Aug 17, 2026; Robert Azelby named Chairman Aug 6, 2026.
- R&D expenses $37.2M (up from $32.8M), G&A $22.6M (up from $11.3M); collaboration revenue $0 vs $3.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526343434/0001193125-26-343434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526343434/tngx-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer